Assessing the impact and risk of immunomodulatory compounds on pregnancy

The HESI Immunotoxicology Technical Committee (ITC) and Developmental and Reproductive Toxicology (DART) Committee are excited to share our latest publication in the Journal of Reproductive Immunology!

Publication overview
This paper explores the impact and risk of immunomodulatory compounds on pregnancy, summarizing key insights from a joint HESI ITC/DART survey and workshop. The study examines immune mechanisms during pregnancy, the adequacy of current tools for assessing risk, and global regulatory considerations across different immunomodulatory therapies.

Why is this important?
For patients and clinicians, making informed medical decisions during pregnancy is one of the most critical moments in life. As immunomodulatory treatments become more common for conditions like autoimmune diseases and cancer, understanding their effects on pregnancy is important for ensuring both maternal and fetal health. This publication provides helpful insights to support decision-making by summarizing current scientific understanding and assessment approaches.

Read the full article here:
Assessing the impact and risk of immunomodulatory compounds on pregnancy. Kwak-Kim et al., 2025. Journal of Reproductive Immunology. https://doi.org/10.1016/j.jri.2025.104453